TransMedics Group, Inc. $TMDX Position Lifted by Baillie Gifford & Co.

Baillie Gifford & Co. grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 21.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 316,473 shares of the company’s stock after purchasing an additional 55,754 shares during the period. Baillie Gifford & Co. owned 0.93% of TransMedics Group worth $38,499,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of TMDX. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group during the third quarter worth $28,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of TransMedics Group during the third quarter worth $29,000. Optiver Holding B.V. raised its holdings in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the period. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Down 0.6%

TMDX stock opened at $113.36 on Tuesday. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a fifty-two week low of $81.92 and a fifty-two week high of $156.00. The firm’s 50-day simple moving average is $123.43 and its 200 day simple moving average is $126.43. The stock has a market cap of $3.89 billion, a PE ratio of 23.13 and a beta of 2.09.

Insiders Place Their Bets

In related news, Director David Weill sold 3,571 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total value of $524,294.22. Following the sale, the director owned 12,134 shares of the company’s stock, valued at $1,781,513.88. This trade represents a 22.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Nicholas Corcoran sold 2,966 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the completion of the sale, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 16,205 shares of company stock worth $2,353,002. 7.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TMDX. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Stifel Nicolaus increased their target price on shares of TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a report on Monday, March 9th. Needham & Company LLC increased their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. TD Cowen reissued a “buy” rating on shares of TransMedics Group in a report on Monday, March 16th. Finally, Oppenheimer increased their target price on shares of TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $152.33.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.